

Functional metagenomics of the thioredoxin superfamily

Sebastian Nilewski¹, Marharyta Varatnitskaya¹, Thorsten Masuch^{1,2}, Anna Kusnezowa¹, Manuela Gellert³, Anne F. Baumann¹, Natalie Lupilov¹, Witali Kusnezow¹, Markus-Hermann Koch⁴, Martin Eisenacher⁴, Mehmet Berkmen², Christopher H. Lillig³, Lars I. Leichert^{1*}

¹Ruhr-Universität Bochum, Institute of Biochemistry and Pathobiochemistry – Microbial Biochemistry, Universitätsstr. 150, 44780 Bochum, Germany.

²New England Biolabs, 240 County Road, Ipswich, MA 01938, U.S.A.

³Ernst-Moritz-Arndt Universität, Institute for Medical Biochemistry and Molecular Biology, Ferdinand-Sauerbruch-Strasse, DZ7, J03-35, 17475 Greifswald, Germany

⁴Ruhr-Universität Bochum, Medizinisches Proteom-Center, PRODI building, Gesundheitscampus 4, D-44801 Bochum, Germany.

*Corresponding author: Lars I. Leichert

E-mail: lars.leichert@ruhr-uni-bochum.de

Running title: Functional metagenomics of the thioredoxin superfamily

Keywords: Thioredoxin, *Escherichia coli* (*E. coli*), thiol, reductase, oxidase, protein disulfide isomerase, TrxA, DsbA, DsbC, thiol-disulfide oxidoreductase

Abstract

Environmental sequence data of microbial communities now makes up the majority of public genomic information. The assignment of a function to sequences from these metagenomic sources is challenging, because organisms associated with the data are often uncharacterized and not cultivable. To overcome these challenges, we created a rationally designed expression library of metagenomic proteins covering the sequence space of the thioredoxin superfamily. This library of 100 individual proteins represents more than 22'000 thioredoxins found in the Global Ocean Sampling dataset. We screened this library for the functional rescue of *Escherichia coli* mutants lacking the thioredoxin-type reductase ($\Delta trxA$), isomerase ($\Delta dsbC$), or oxidase ($\Delta dsbA$). We were able to assign functions to more than a quarter of our representative proteins. The *in vivo* function of a given representative could not be predicted by phylogenetic relation but did correlate with the predicted isoelectric surface potential of the protein. Selected proteins were then purified, and we determined their activity using a standard insulin reduction assay and measured their redox potential. An unexpected gel shift of protein E5 during the redox potential determination revealed a redox cycle distinct from that of typical thioredoxin-superfamily oxidoreductases. Instead of the intramolecular disulfide bond formation typical for thioredoxins, this protein forms an intermolecular disulfide between the attacking cysteines of two separate subunits during its catalytic cycle. Our functional metagenomic approach proved not only useful to assign *in vivo* functions to representatives of thousands of proteins, but also uncovered a novel reaction mechanism in a seemingly well-known protein superfamily.

Introduction

The thioredoxin superfamily (1) is an ancient protein family. It is assumed that the first thioredoxins arose ~4 billion years ago, close to the first occurrence of life on planet earth (2). The active site of thioredoxin-like proteins consists of a Cys-X-X-Cys (CXXC) motif located at the N-terminus of an alpha helix (see (3) and (4) for comprehensive reviews). In a redox reaction, the side chains of the two cysteines in this active site

motif can switch from the free thiol (SH) form to a disulfide bond (S-S) and/or back and hence donate or accept electrons. The biological function of thioredoxin-like proteins is determined by the preference of the active site to either accept or donate electrons, and also depends on the cellular redox context. The majority of thioredoxin superfamily members can be categorized into three major functional groups: thiol-disulfide reductases, which donate electrons in reduction reactions, oxidases, which accept electrons and oxidize their substrates, or isomerases, which rearrange disulfide bonds in substrate proteins. The thioredoxin fold (5) is highly versatile and thus members of the thioredoxin superfamily can have highly specialized functions, including reductases for specific substrates, e.g. arsenate reductase (6). Some proteins with thioredoxin fold have further evolved to functions completely unrelated to redox reactions and do not even require a CXXC motif, such as calsequestrin (7).

While the biological function of a thioredoxin protein seems to be based on the redox potential of the hallmark CXXC-motif, the activity towards substrates, and the subcellular context of the redox partners (8), the structure-function relation in this protein class is not fully understood and hard to conjecture. Even with extensive structural information the prediction of the redox potential of thioredoxins is challenging (9), and, to our knowledge, a prediction based on primary structure has not yet been attempted.

With the recent surge in the study of metagenomes, our knowledge about the primary structure of proteins in general and thioredoxins in particular, has expanded substantially. In metagenomic projects, DNA from microbial communities is sequenced without the need for the isolation of individual organisms. Even in traditional genomics, the assignment of functions to protein-encoding genes is still a major bottleneck. In the metagenomic era, because the DNA sequenced is largely of microbial origin and the majority of microorganisms cannot be cultivated in the lab yet, functional assignment has become arguably even more challenging.

In this study we attempt to overcome these challenges by utilizing the vast genetic information contained in metagenomes. For this, we devised a

combination of bioinformatics, synthetic biology, and well-established *Escherichia coli* genetics to functionally characterize the thioredoxin superfamily. As the underlying dataset for our study, we chose the Global Ocean Sampling (GOS) dataset, one of the largest metagenomic datasets to date (10). In a first step we used bioinformatics to identify all thioredoxin superfamily members in this dataset. Then we categorized them into subfamilies, using a markov clustering algorithm. We then identified 100 proteins representing these subfamilies and, using synthetic genes, expressed them in *E. coli*. Using knock-out *E. coli* strains lacking thioredoxin type reductases, oxidases or isomerases, we could assign functions to these representatives based on complementation assays. Analyzing the predicted isoelectric surface potential, we were able to predict reductase function *post hoc*. We then purified and biochemically characterized selected thioredoxins, finding that neither *in vitro* activity nor redox potential correlates with function. Our data provides, to our knowledge, the biggest set of thioredoxin proteins with a known redox potential. One particular thioredoxin, E5, was shown to have an unprecedented mechanism of action, being an oligomer with an intermolecular disulfide bond forming between the attacking cysteines of 2 subunits during its catalytic cycle.

Results and Discussion

Categorization of thioredoxin superfamily members from a metagenomic dataset

In order to advance our understanding of the structure-function relationship of the thioredoxin superfamily, we wanted to categorize all thioredoxin superfamily members found within the GOS dataset into the three major groups: reductases, oxidases, and isomerases. First, we selected all sequences from a non-redundant GOS dataset that matched to any of the Hidden Markov Models (HMM) of the PFAM thioredoxin clan (CL0172) with a score below 10^{-5} (11). Of these 22'860 matches, we removed all 18'187 sequences that did not include an unambiguous start methionine or a stop codon. These "incomplete" thioredoxin sequences were excluded, as it is not possible to synthesize a functional gene from these sequences. We further removed 3 sequences that

did not contain cysteines at the active site found at the N-terminus of the first alpha-helix, reducing the set to a total of 4'673 complete thioredoxins. We then used a Markov Cluster (mcl) algorithm to divide the thioredoxin set into subfamilies (12). The algorithm defined 49 clades, which ranged in size from 1 to 1064 sequences (See table S1 for accession numbers).

Next, we created phylogenetic trees of these clusters and calculated from these trees the mean evolutionary distance for each individual sequence to all other sequences within the tree. This mean evolutionary distance essentially provided us with a measure for the relationship distance of any individual protein to all other proteins within a cluster. The protein most closely related to all other cluster members was defined as the representative of that cluster (table S1). In exceptionally large clusters we chose additional proteins with greater mean evolutionary distances to cover the whole diversity of those families (table S1, figure 1). In this way we were able to select 100 individual proteins representing the totality of the thioredoxin universe in the GOS dataset. Genes encoding these proteins were then codon optimized for *E. coli* and synthesized (see supplementary material S1 for the protein sequences of the synthesized genes).

Functional complementation assays

To assign functions to these 100 representative proteins, we developed a complementation system in *E. coli*. The three major functional groups of thioredoxin superfamily members are represented in *E. coli* by the proteins Thioredoxin 1 (TrxA, a reductase), DsbA (an oxidase) and DsbC (an isomerase). Based on the phenotypes of mutants lacking these proteins, we established complementation assays with the help of a set of vectors that introduce the metagenomic thioredoxins into *E. coli* mutants. These vectors express one of the 100 synthetic genes in the cytoplasm (plasmid for cytoplasmic complementation, pCC) or the periplasm of *E. coli* (plasmid for periplasmic complementation, pPC), or express them with an N-terminal, TEV protease-cleavable His₆ tag for purification (plasmid for overexpression pOE) (figure 2, vector sequences: supplementary material S2). The individual complementation assays were set up as follows:

Reductase assay

E. coli TrxA is a cytoplasmic thiol-disulfide reductase that reduces disulfide bonds in several essential cellular reactions, among them a disulfide bond in PAPS (3'-Phosphoadenosine-5'-phosphosulfate) reductase that is generated during sulfate assimilation (13). The glutathione dependent glutaredoxins can compensate for the lack of TrxA, but a $\Delta gor \Delta trxA$ double mutant, which also lacks the ability to re-reduce glutathione, is unable to grow in minimal medium containing sulfate as the sole sulfur source (14) (see figure 3 A for a schematic overview). The re-introduction of a disulfide reductase, such as *E. coli* TrxA or a metagenomic thioredoxin with reductase activity from a plasmid should rescue growth of this mutant in minimal medium. By expressing our 100 synthetic genes in this strain from the pCC plasmid, we identified 15 reductases in the set of metagenomic thioredoxin superfamily members (figure 3 B, figure 4 A).

Oxidase assay

DsbA is a thiol-disulfide oxidase that introduces structural disulfides during oxidative folding in *E. coli*'s periplasm (15). Among DsbA's substrates is FlgI, a protein essential for the formation of the bacterial flagellum. Thus, $\Delta dsbA$ null mutants are non-motile (16) (see figure 3 C for a schematic overview). A thiol oxidase expressed from a plasmid containing a periplasmic signal sequence should restore motility of that mutant. *E. coli* DsbA is able to restore that phenotype, as are 12 representative metagenomic thioredoxins (figure 3 D figure 4 B).

Isomerase assay

The isomerase DsbC rearranges disulfide bonds in periplasmic proteins (17). This function is particularly needed during folding of proteins containing non-consecutive disulfide bonds in their structure (18). RcsF is a protein dependent on DsbC's activity and is at the beginning of a cascade that activates colanic acid capsule synthesis upon perturbation of the envelope (19). A $\Delta mdoG (=opgG)$ mutant lacks osmoregulated periplasmic glucans and usually compensates this RcsF-dependently by an excess in colanic acid production (20). Colonies of $\Delta mdoG$ strains thus appear mucoid at low growth temperatures (21). However, because RcsF is inactive in the absence of DsbC, a $\Delta mdoG \Delta dsbC$ double mutant has a

regular colony shape (22) (see figure 3 E for a schematic overview). A disulfide isomerase expressed from a plasmid and exported into the periplasm should lead to a mucoid colony shape in this mutant. In addition to *E. coli* DsbC, 12 metagenomic representative thioredoxins led to a restoration of the mucoid phenotype of this strain (figure 3 F, figure 4 C).

27 out of 100 thioredoxins show an in vivo function

With these three assays at hand, we were able to assign a function to 27 of our 100 thioredoxin superfamily members (figure 4). Based on the high-throughput nature of our assay, we cannot conclude that the other 73 proteins are inactive, as the probability of false negatives in such an approach is high. 12 of the metagenomic thioredoxins showed overlapping activities, i.e. they rescued more than one phenotype (figure 5 A). The natural propensity of thioredoxin superfamily members to be functionally promiscuous, especially in regard to isomerase and oxidase activity, is already notable in eukaryotes, where those functions are achieved by a single protein (PDI). The observed promiscuity, however, was in contrast to their *E. coli* counterparts, which were exclusively able to rescue their own phenotype (figure 6).

A thioredoxin's in vivo function is linked to its isoelectric surface potential

The overlapping activity of some thioredoxins already demonstrated the high plasticity of this protein family, although this promiscuity might in part be induced by the artificiality of our assay, such as unnatural high expression levels. To elucidate the connection between functionality and protein evolution, we then determined the phylogenetic relationship of the functionally complementing thioredoxins to their *E. coli* counterparts (figure 5 B-D, see also figure 1). Our set of 100 thioredoxin superfamily members contained a number of canonical folds and active sites typical for thioredoxins, glutaredoxins, glutathione-S-transferases, NrdH glutaredoxin-like proteins, Arsenate reductases, protein disulfide isomerases, Peroxiredoxins, and Glutathion-peroxidases (table S2). Of those, only thioredoxin, glutaredoxin, PDI, and Dsb-family members showed activity in our complementation assay. However, the wide diversity we found among those families and the

fact that the fold did not necessarily align with the observed function suggested that phylogenetic relation is not a good predictor for thioredoxin function. Similarly, an analysis of the secondary structure based on structural predictions suggested that thioredoxins can share the same *in vivo* function, although their primary and secondary structure have substantially diverged, while presumably structurally similar thioredoxins can have opposing functions (see supplementary material S4). Dissatisfied with our inability to predict the function of a thioredoxin based on a phylogenetic or simplistic structure analysis, when we then calculated the isoelectric surface potential (isosurfaces) of these proteins (figure S1). These results suggested that electrostatic fields emanating from the proteins play a large role in the *in vivo* function of these proteins. The isoelectric surface potential of the 15 proteins functioning as reductases showed a striking similarity to that of *E. coli* TrxA (figure 5 E-G), suggesting that in the case of reductases the electrostatic interactions between the metagenomic proteins and their *E. coli* substrate are a determinant of the protein's *in vivo* function.

Oxidoreductase activity of metagenomic thioredoxins

To verify the *in vivo* activity derived from our complementation assays and to further substantiate the relationship between protein function and predicted isosurfaces, we purified and biochemically characterized selected thioredoxins from the set of 27 thioredoxins showing activity in *E. coli*. Thioredoxin superfamily members share the ability to catalyze the reduction of insulin by DTT (23). We used this classical insulin reduction assay to determine the activity of the respective metagenomic thioredoxins. In our assay, a FITC-labeled insulin was incubated with DTT and a metagenomic thioredoxin superfamily member was added as a catalyst (figure 7 A). The reduction of insulin and separation of the 2 chains could be monitored spectrofluorometrically. The initial velocity was used as a measurement for activity. All active metagenomic thioredoxins examined showed insulin reduction activity. However, the activity of any given metagenomic thioredoxin did not correlate with its *in vivo* function (figure 7 B).

The metagenomic thioredoxins span a wide range of redox potentials

In addition to the kinetic parameter of insulin reduction activity, the standard redox potential is an important thermodynamic factor for thioredoxin function. The redox-potential essentially determines the possible direction of the electron flow between partners in a redox network. In *E. coli*, the function of the three paradigmatic proteins TrxA (reductase with a redox-potential of -270 mV), DsbA (oxidase with a redox-potential of -120 mV) and DsbC (isomerase with a redox-potential of -130 mV) correlates with their redox-potential, with the reductase TrxA having the most reducing and the oxidase DsbA the most oxidizing active site (24–26). We, therefore, determined the redox potential of the selected thioredoxin-superfamily members by incubation in redox-buffers and subsequent 4-acetamido-4'-maleimidylstilbene-2,2'-disulfonic acid (AMS) labeling of free thiols. AMS chemically modifies reduced thiols and thus leads to retardation in a non-reducing SDS PAGE. Based on this we could determine the oxidized and reduced portion of a protein densitometrically and thus determine the mid-point redox potential (figure 7 C). It is important to realize that the half-cell potential and the flow of electrons within the cell is not solely determined by the standard redox potential of the redox partners, but often imposed by other systems: the NADPH and thioredoxin reductase transfer electrons and protons to oxidized TrxA; DsbB accepts electrons from reduced DsbA and donates them to ubiquinone; DsbD keeps DsbC reduced, in a Trx system-dependent manner. Consequently, some of the proteins with a mid-point redox potential lower than *E. coli* TrxA could also rescue the isomerase or oxidase phenotype *in vivo*, despite the substantial difference in their mid-point redox potential when compared to the *E. coli* protein they were complementing. The most extreme example was F12, which had a redox potential of -312 mV but could replace DsbA with a redox potential of -120 mV, (figure 7 D).

E5, an unusual thioredoxin

During their catalytic cycle, thioredoxins typically form an intramolecular disulfide bond in their hallmark CXXC motif (27). In our *in vitro* characterization experiments, one metagenomic thioredoxin representative did not show this expected reaction mechanism of thioredoxin superfamily members. Instead, it formed an

intermolecular disulfide bond, resulting in dimer formation, which we could observe in our gel shift assays when we determined the proteins redox potential. This particular thioredoxin, E5, which rescued the oxidase and isomerase phenotypes in *E. coli*, can also effectively replace the disulfide isomerase in a commercial strain used to fold challenging proteins (*E. coli* SHUFFLE™). We tested E5's biotechnological potential in this strain with alkaline phosphatase (PhoA) and acidic phosphatase (AppA) from *E. coli*, urokinase, and a truncated version of human tissue plasminogen activator (vtPA) as substrate proteins. While E5 was as effective as DsbC to help form the correct disulfide bonds in PhoA and vtPA, it was significantly more effective in folding AppA (figure 8 A).

In vitro, E5 showed the highest insulin reduction activity of all thioredoxins tested (figure 7 B, figure 8 B) and, most unusually, formed a dimer upon oxidation. We observed this dimer formation in non-reducing SDS PAGE (figure 8 C, D).

To elucidate if the observed dimer was an artifact of our experimental setup, we asked, if it was also part of the catalytic cycle of E5. We thus used reduced E5 in a reaction with insulin, where the reductant DTT was omitted (figure 8 E). Under these conditions, E5 did, in fact, reduce insulin and formed a disulfide-linked dimer as well (figure 8 F). We could exclude dimer formation through air oxidation, as no dimer formation was observed in the assay when omitting insulin. We thus concluded that dimer formation was indeed part of the catalytic cycle.

Because E5 possesses 2 cysteines, both located in the active site, we argued that dimer formation must involve at least one cysteine from each subunit or even both cysteines. To test for these possibilities, we determined the presence of free cysteines in the reduced and oxidized forms of E5 in an Ellman's assay. This assay, which uses the propensity of free thiols to release the yellow compound thiol-nitro benzene (TNB) from Ellman's reagent (DTNB), showed that the oxidized form contains half as many available cysteines per subunit than the reduced form, suggesting to us that only one cysteine from each subunit was involved in dimer formation (figure 9).

In thioredoxins, the N-terminal cysteine of the CXXC-motif is considered the "attacking" cysteine and typically interacts with the substrate first, while the C-terminal cysteine is the "resolving" cysteine, completing the reaction cycle (28). We argued that instead of relying on the resolving cysteine, E5 could rely on the attacking cysteine of another E5 molecule to complete the reaction cycle. A mutant protein lacking the C-terminal, resolving cysteine (C77S) should therefore still be able to form the disulfide-linked dimer upon oxidation. Although it does not rescue the DsbA phenotype in *E. coli* (figure 10), suggesting the resolving cysteine is needed *in vivo* for oxidase activity, it is indeed able to form the disulfide *in vitro* (figure 8 G). More importantly, this mutant is still catalytically highly active in the insulin reduction assay (figure 8 H). The presence of DTT in our insulin reduction assay could potentially compensate for the lack of the resolving cysteine under these circumstances, although the formation of a disulfide bond in the wild-type in the assay without DTT (figure 8 E) indicates that DTT is not needed to resolve the insulin-E5 adduct. This is in contrast to typical thioredoxins, where mutants in the resolving cysteine of thioredoxins cannot complete their catalytic cycle, even in the presence of DTT. This fact has successfully been exploited to trap thioredoxin protein-substrate complexes for the identification of substrate proteins (29). In contrast, a C74S variant of E5 (lacking the attacking cysteine) did not show any activity in an insulin reduction assay (figure 8 H).

To elucidate if E5 already forms a dimer under reducing conditions, we performed a size exclusion chromatography in the presence of reducing agent. An E5 monomer has a molecular weight of 23580 Da, and a blast search reveals a DsbA/Com1-like domain. DsbA itself is known to form a dimer. The elution profile of E5 and its C77S variant showed a peak at an apparent molecular weight of ~153 KDa, consistent with a hexameric quaternary structure (figure 8 I), suggesting, together with the observation of a covalent linkage upon oxidation, that E5 forms a trimer of dimers, each with its active site cysteines in close vicinity. Such a hexameric structure could enhance the propensity of intermolecular disulfide bond formation between the subunits. Given that DsbC is a natural dimer, E5's multimeric structure and its CGYC active site

hint at a potential isomerase function in its unknown native host, with a redox potential that makes it prone to oxidation in *E. coli*'s periplasm.

Conclusion

Our functional metagenomics approach applied to the GOS dataset highlights the functional plasticity of the ancient thioredoxin superfamily by screening a select set of functions typical for these proteins. Depending on the cellular context, the *in vivo* function of a thioredoxin protein can change, and even be reversed. The determined redox potential, as well as insulin reduction activity do not correlate with *in vivo* activity but seems to be dependent on the protein's isoelectric surface potential. Our comprehensive screening revealed a novel thioredoxin-like protein. This protein only needs a single cysteine to function and relies on dimerization to complete its reaction cycle, has a hexameric quaternary structure, and shows higher activity in an insulin reduction assay than *E. coli* thioredoxin.

Experimental Procedures

Definition of thioredoxin superfamily members from the GOS dataset

All predicted protein sequences from the GOS dataset were obtained from NCBI BioProject 13694 (Accession: PRJNA13694). Redundancy of this dataset was then reduced to 90 % using Cd-Hit (30). The sequences from this non-redundant GOS dataset were then matched to Hidden Markov Models (HMM) of the PFAM thioredoxin clan CL0172 using HMMER (version 3.0) (11, 31). All sequences that matched with a score below 10^{-5} were considered for further analysis. Sequences, which did not contain an unambiguous start or stop codon in their associated DNA scaffolds were removed to obtain only complete protein sequences. Sequences not containing at least one cysteine in the hallmark CXXC motif were removed, leaving a total of 4'673 sequences. This set was then divided into 49 subfamilies using the MCL clustering algorithm with an inflation parameter of I=6 as described (12) (see table S1).

Selection of representative sequences

UPGMA trees of each cluster were created using MAFFT (version 7) and saved in the Newick format

(32). In these trees, the sum of the phylogenetic distance for each individual protein to all other proteins was calculated from the individual branch lengths in the tree file (see supplementary material S5 for the lisp program used). The sequence with the smallest overall distance was chosen as the representative sequence. For clusters with more than 50 members, additional sequences were chosen, so that at least 50 and at most 100 sequences were associated with a representative sequence. Said additional sequences were chosen in an equidistantly distributed manner based on BLASTP bit scores between the representatives and all other cluster members (see table S1). 96 protein sequences were denominated arbitrarily A1-A12, B1-B12, ..., H1-H12 based on positions in a microwell plate (table S1). Four additional protein sequences were chosen by an initial BLASTP similarity search to *E. coli* TrxA (R1 and R2), DsbA (O1), and DsbC (I1) (NCBI GI accession: 140401181, 143027041, 142228890, 136774375). All protein sequences of synthesized genes can be found in supplementary material S1, accession numbers for all selected superfamily members found in the GOS dataset can be found in table S1.

Codon optimization, sequence analyses, and gene synthesis

Codon usage was optimized for protein expression in *E. coli* with the help of the online tool JCat (33). Interfering restrictions sites (*Nde*I, *Eco*RI, *Bam*HI) were excluded during codon optimization. Incorrectly annotated N-termini from mistakenly assigned start methionines in the metagenome-derived contigs were removed based on a comparison with homologous proteins using BLAST (34). If the start methionine of a substantial number of homologous proteins mapped to an "internal" methionine of the target gene, the N-terminus was shortened accordingly prior to codon optimization. Leucine, isoleucine or valine were taken into consideration as potential starting positions, since codons of these amino acids can function as alternative start codons (35). Prediction of potential signal sequences was done with the help of SignalP (36). Default parameters were used, except "Organism group", which was set to "Gram-negative bacteria". Sequence analysis (extinction coefficient calculation, molecular weight determination) was performed with the ProtParam

tool (37). Gene synthesis was performed by Life Technologies (GeneArt, Darmstadt, Germany).

Strain construction and strain maintenance

E. coli strains and plasmids used in this study are listed in table S3. For liquid cultures, an appropriate volume of LB medium (10 g/L tryptone, 10 g/L NaCl, 5 g/L yeast extract) was inoculated with a single colony of the strain of interest and grown overnight at 37 °C, shaking at 125 rpm. Media were supplemented with 200 µg/mL kanamycin and/or 100 µg/mL ampicillin, if appropriate. This pre-culture was used to inoculate a main culture to an OD₆₀₀ of 0.05 and growth was followed spectrophotometrically. For long-term storage of strains, samples of overnight cultures were supplemented to 12 % (v/v) glycerol and stored at -70 °C. For re-cultivation, glycerol stocks were streaked out on LB agar plates (LB medium with 15 g/L agar) containing the appropriate antibiotics and incubated overnight at 37 °C.

Molecular cloning

In general, cloning procedures were carried out according to standard protocols(38). All enzymes for cloning work were obtained from Thermo Scientific (Waltham, MA). Genes were amplified via PCR generating necessary restriction sites through primer-overhangs (primers and oligonucleotides used in this study are listed in table S3). Genomic DNA of *E. coli* BW25113 served as template DNA for the amplification of *E. coli* genes (39). For the amplification of metagenes, standard vectors containing these synthesized metagenes were used as templates. For analysis and purification, PCR products were loaded on 1 % agarose gels and separated by electrophoresis. PCR products were cut from the gel and purified using the NucleoSpin Extract II Kit (Macherey-Nagel, Düren, Germany). PCR product and target vector were digested with FastDigest enzymes according to the manufacturer's recommendations and purified on a gel as mentioned. Vector DNA was dephosphorylated with FastAP phosphatase and insert DNA was phosphorylated with T4 polynucleotide kinase according to the manufacturer's protocol and purified on a gel. Ligation was performed in 20 µL samples using T4 ligase according to the manufacturer's recommendations. Subsequently, competent *E. coli* XL1-Blue cells were directly transformed with 4

µL of the ligation sample and finally streaked out on LB agar plates containing ampicillin. Clones were grown overnight at 37 °C and plasmid constructs were isolated using the NucleoSpin Plasmid Kit by Macherey-Nagel. Construct sequences were verified by DNA sequencing (Eurofins MWG Operon, Ebersberg, Germany).

Plasmids

Complementation vectors pCC and pPC were constructed by modifying the commercially available pTAC-MAT-Tag-2 vector (Sigma-Aldrich, St. Louis, MO). For pCC, an *NdeI* restriction site was introduced by site-directed mutagenesis so that it contained the original start codon of the vector. The primers QCNde_For_neu and QCNde_Rev_neu were used (see table S3 for primers used). Plasmid isolation and verification were performed as described above. For pPC, the signal sequence of *E. coli ompA* was inserted between *NdeI* and *HindIII* sites of pCC according to the strategy described by Rentier-Delrue and co-workers (40). The *ompA* signal sequence (*ompAss*, nucleotides 1-63) was amplified via PCR with primers *ompASS_for(Nde)* and *ompASS(Hin)_rev*. The *ompAss* flanked by *NdeI* and *HindIII* sites was ligated into pCC. Plasmid isolation and verification were performed as described above. In order to allow for standardized cloning via *NdeI* and *EcoRI*, an *NdeI* restriction site had to be introduced at the 3' end of the *ompAss*. First, the *NdeI* site at the 5' was destroyed by site-directed mutagenesis with mutagenic primers pPCQCforward and pPCQCreverse. For the introduction of a new *NdeI* site at the 3' end of *ompAss*, a round-the-horn mutagenesis was performed (41). First, primers pJH1-RTH-Forward and pJH1-RTH-Reverse were phosphorylated by mixing for each primer 1 x polynucleotide kinase (PNK) buffer, 1 mM MgSO₄, 10 µM of primer, 2 mM ATP, and 10 U PNK. After incubation for 30 min at 37 °C PNK was heat-inactivated for 10 min at 75 °C. Then, a PCR with 1 x Pfu Turbo polymerase, 0.3 µM of each primer, 200 µM dNTPs, 100 ng pPC (after site-directed mutagenesis from above), and 2.5 U Pfu Turbo polymerase was performed using the following program: 98 °C / 1 min, (96 °C / 30 s, 55 °C / 30 s, 68 °C / 10 min 30 s) for 25 cycles. Plasmid isolation and verification were performed as described above. Commercially available pET11a (Novagen, Darmstadt, Germany)

was used to design pOE. First, the single *EcoRI* site within pET11a was destroyed using site-directed mutagenesis and mutagenic primers pETdestroyEco_f and pETdestroyEco_r. Then, an *EcoRI* site was introduced between the single *NdeI* site and the T7 terminator using the mutagenic primers pETintroEco_f and pETintroEco_r. Finally, a double stranded oligonucleotide, which contained a His₆ tag and a TEV protease cleavage site (ENLYFQG), was introduced between *NdeI* and *XbaI*. Two complementary oligonucleotides which contained *NdeI* and *XbaI* overhangs were mixed in equimolar amounts, heated to 95 °C for 2 min and cooled on ice for 2 min. Subsequently, the insert was ligated into linearized vector as described above. Plasmid isolation and verification was performed as described above.

Reductase Assay

Reductase activity was tested in liquid M9 minimal medium containing 5 µM IPTG for the induction of protein expression. M9 minimal medium was prepared according to (38). Single colonies of *E. coli* Δ trxA Δ gor strains carrying different plasmid constructs were transferred to the medium and incubated for two days at 30 °C in a roller drum. Growth was determined spectrophotometrically at 600 nm. These assays were performed in three independent experiments. Strains that reached overnight an OD₆₀₀ > 0.2 in all experiments were considered to express a metagenomic reductase.

Oxidase Assay

For the oxidase activity assay, semi-solid LB agar plates (0.35 % (w/v) agar) containing 5 µM IPTG were prepared. Single colonies of *E. coli* Δ dsbA mutant strains carrying different plasmid constructs were transferred to the center of the plates. Then, plates were incubated for 24 h at 37 °C. After incubation plates were inspected for cell halos indicating DsbA substitution. Strains that produced halos around the inoculation site in three independent experiments were considered to express a metagenomic oxidase.

Isomerase Assay

For the isomerase activity assay, MOPS agar plates containing 50 µM IPTG were prepared. MOPS medium was obtained from Teknova (Hollister, CA) and prepared according to Neidhardt (42). Single colonies of *E. coli* Δ dsbC Δ mdoG double

mutant strains carrying different plasmid constructs were streaked out on the plates followed by an incubation for 24 h at 30 °C. Three independent experiments were performed and only strains that showed a mucoid phenotype in all three experiments were considered to express a metagenomic isomerase.

Secondary structure prediction and isosurface calculation

The secondary structure of thioredoxins was predicted using SWISS-MODEL (43). For isosurface calculation, the sequences of the 103 selected thioredoxin superfamily members were blinded and the secondary structure was predicted using the automodel function of SWISS-MODEL (43). Computation of the protein electrostatic properties from the pdb files were done as follows: the reconstruction of any missing atoms, the addition of hydrogens, the assignment of atomic charges and radii was performed using pdb2pqr with the amber force field (44). All resulting secondary structures were aligned and oriented in the visual molecular dynamics program VMD (45) based on the structures of *E. coli* TrxA (PDB entry 1xoA) or *E. coli* Grx1 (PDB entry 1egr). Within the VMD software package, the Adaptive-Poisson-Boltzmann Solver (APBS) (46) was used to calculate the electrostatic potential that is visualised as isosurface and also mapped to the protein surface. Parameters for the calculations were set to 298 K, 150 mM mobile ions in aqueous solution. Images depicting the secondary structure (N-terminal active site cysteinyl residue facing towards camera perspective), the electrostatic potential mapped to the surface (from -4 K·T·e⁻¹ in red to 4 K·T·e⁻¹ in blue), and the isosurface of the electrostatic potential (from -1 K·T·e⁻¹ in red to 1 K·T·e⁻¹ in blue) were rendered.

The hydrophobicity of the surface was analysed using Chimera (47). The computation was done using the amino acid hydrophobicity in the Kyte-Doolittle scale depicted in red (hydrophobic) and blue (hydrophilic). An overview of all blinded structures (figure S1) was independently evaluated by 2 researchers to predict functional candidates. Using this strategy, unblinding revealed that 11 out of 16 structures of proteins that functioned in the Δ gor/ Δ trxA complementation assay, were predicted correctly (figure S1, marked with an asterisk) with

no false positives. No Isosurfaces could be calculated for A2, A9, B8, E10, and F6, as no suitable model for structure prediction was found.

Protein purification

The genes of proteins, which were predicted to possess a signal sequence, were cloned into pOE with the signal sequence removed. This was the case for O1, I1, H3, H8, B11, D6, D11, and E5. Single colonies of *E. coli* BL21(DE3) carrying the respective overexpression plasmids were inoculated in 50 mL LB medium containing ampicillin and grown overnight at 37 °C. Then, a 5 L main culture was inoculated with the pre-culture and incubated to an OD₆₀₀ of 0.5 at 37 °C. 1 mM IPTG and fresh ampicillin were added and the culture was incubated overnight at 20 °C. Cells were harvested by centrifugation (30 min at 4 °C 7'800 x g). The cell pellet was resuspended in 100 mL of buffer A (50 mM sodium phosphate, 300 mM NaCl, pH 8.0) including two dissolved pills of an EDTA-free protease inhibition cocktail (Roche, Mannheim, Germany) and 1 mM PMSF. Then, cells were disrupted using a high-pressure cell disruption system at 1.9 kbar (Constant Systems, Low March, UK). Cell lysate was centrifuged for 1 h at 4 °C and 67'500 x g. Supernatant was filtered using "Filtropur" 500 mL vacuum filters (Sarstedt, Nümbrecht, Germany). Purification and fractionation steps were performed with an "ÄKTApurifier" FPLC system (GE Healthcare Freiburg, Germany). Filtrate was loaded onto 2 x 5 mL Ni-NTA-columns "HisTrap™ HP" (GE Healthcare) equilibrated with buffer A. Elution was performed with 6 column-volumes of buffer B (buffer A containing 500 mM imidazole). 3 mL fractions were collected and analyzed by SDS PAGE. Fractions with the highest target protein yield were pooled and His₆-tagged TEV protease was added (30-fold excess of target protein to TEV protease). Protein solution was dialyzed against buffer A in Spectra/Por dialysis tubes with a pore size of 6-8'000 MWCO (spectrumlabs.com, Breda, Netherlands), overnight at 4 °C. Then, the protein solution was loaded onto the Ni-NTA-columns to remove the His₆-tagged TEV protease, as well as the cleaved His₆ tag. Flowthrough containing the protein was dialyzed against 100 mM sodium phosphate buffer (pH 7.0) containing 1 mM EDTA

and concentrated in Amicon Ultra concentrators pore size 3'000 MWCO (Millipore, Darmstadt, Germany).

Overexpression and purification was modified for R1, since it was highly insoluble in test expression experiments. A single colony of *E. coli* BL21(DE3) carrying pSN61 was transferred into 5 mL LB medium containing ampicillin and incubated for 90 min at 37 °C. Then, cell suspension was transferred into a 5 L main culture and grown overnight at 37 °C without shaking. Then, the culture was grown under shaking to an OD₆₀₀ of 0.5 and IPTG induction was performed as described above. After growth for 4 h at 37 °C, cells were harvested as described above. The cell pellet was resuspended in buffer A. Cell disruption and centrifugation were performed as described above. The insoluble pellet was resuspended in 50 mL of 8 M urea. This protein solution was slowly dissolved in 5 L PBS (pH 7.4) and stirred at 4 °C overnight for refolding. Then, protein solution was centrifuged for 1 h at 4 °C and 15'500 x g to remove remaining unfolded protein. The supernatant was filtered as described above. The entire filtrate was loaded onto one 5 mL Ni-NTA-column overnight at 4 °C using a peristaltic pump. Elution and further purification steps were performed as described above. Buffer A was supplemented with 2 mM β-mercapto-ethanol.

Proteins H3, B11, H8, D6, D11, and E5 were predicted to contain a signal sequence. For cytoplasmic overexpression predicted signal sequences were removed by PCR and genes cloned into pOE as described above. Overexpression was done as for O1, I1 and R1 but on a 1 L scale. Cleared cell lysate was loaded onto a self-packed column using 1 mL Ni-NTA agarose (Qiagen, Hilden, Germany) in Poly-Prep Chromatography Columns (Bio-Rad, Munich, Germany). Purification was performed according to the manufacturer's protocol. This protocol was also used for C4, C12, B1, A8, H11, E1, D4, F12, G5, and the C-terminal cysteine mutant of E5. After purification, His₆ tag removal was achieved as described above. However, His₆ tag removal could not be successfully achieved for B1, C4, D6, D11, E5, and G5, presumably due to structural inaccessibility. These proteins were characterized still containing the His₆ tag.

Insulin reduction assay

FITC-labeled insulin reduction was monitored fluorometrically with a fluorescence spectrophotometer FP-8500 (Jasco, Tokyo, Japan) equipped with a Peltier-thermo cell holder EHC-813. Emission was followed over time at a wavelength of 520 nm. Excitation wavelength was 490 nm. Emission and excitation bandwidth was 2.5 nm, response was 1 s and sensitivity was low. Samples were prepared in a quartz cuvette Suprasil for fluorescence measurements (Hellma, Müllheim, Germany). General sample composition was adopted from Holmgren (23) and slightly modified using FITC-labeled insulin (Sigma-Aldrich). 20 mM potassium phosphate buffer (pH 7.0), 2 mM EDTA, 330 μ M DTT and 10 μ g/mL FITC-labeled insulin were added in that order and the measurement was immediately started at 25 °C while stirring (800 rpm). After the fluorescent signal was stable, the protein of interest was added to a final concentration of 1 μ M. As control, protein was omitted to follow uncatalyzed reduction by DTT. For one reaction cycle catalysis, DTT was left out and reduced protein was added. Protein was reduced using 1 mM DTT and DTT was subsequently removed using an “illustra NAP-5 column” (GE Healthcare).

The initial slope of fluorescence increase after addition of proteins was used to determine protein activity (rate of FITC-labeled insulin reduction per time per mol protein). The initial slopes were determined with the "Spectra analysis / Kinetics" mode of the measurement control and evaluation program "Spectra Manager 2.09.01" (Jasco). Activity of *E. coli* TrxA was set to 100 %.

Redox potential determination

In an anaerobic chamber (Coy Laboratories, Grass Lake, MI, USA) proteins of interest (20 μ M) were completely oxidized with 1 mM diamide for 1 h at 37 °C to produce fully oxidized protein. Then, diamide was removed using an “illustra NAP-5 column” (GE Healthcare). Proteins were eluted from the column in 100 mM sodium phosphate buffer (pH 7.0) containing 1 mM EDTA. Then, they were mixed with GSH/GSSG redox buffers containing increasing GSH concentrations (1 μ M to 200 mM) and constant GSSG concentrations (100 μ M in case of O1, 10 μ M in all other cases). Control samples containing only GSH and only GSSG were prepared to fully reduce and fully oxidize proteins.

The pH of samples containing GSH concentrations above 50 mM was adjusted to pH 7.0 by adding concentrated NaOH. Samples were incubated overnight at 25 °C under slight shaking at 400 rpm in a Thermo Mixer (Eppendorf, Hamburg, Germany). After incubation, proteins were precipitated with 10 % (w/v) TCA for 20 min on ice. Samples were spun down for 30 min at 4 °C and 18'000 x g. The supernatant was discarded, the pellet washed in 60 μ L of 10 % TCA and in 20 μ L of 5 % TCA. In a final centrifugation step, the protein pellet was dried completely to remove any residual TCA. Protein pellets were then resuspended in 20 μ L of 50 mM AMS in denaturing alkylation buffer (DAB, 6 M urea, 200 mM Tris-HCl (pH 8.5), 10 mM EDTA, 0.5 % (w/v) SDS) (48). In a Thermo Mixer, samples were incubated for 1 h at 25 °C and 1'300 rpm in the dark. Then, samples were incubated for 5 min at 95 °C in 1 x non-reducing SDS loading buffer (2 % (w/v) SDS, 12 % (v/v) glycerol, 60 mM Tris-HCl (pH 7.0), 0.0001 % (w/v) bromophenol blue) and loaded onto a pre-cast NuPAGE Novex 4-12 % Bis-Tris protein gel (Life Technologies). The gel was run under non-reducing conditions at 300 V and 110 mA and Coomassie stained.

Evaluation of protein band patterns was performed by integrated density measurements using Photoshop CS5 Extended 12.0 (Adobe, San Jose, CA) and ImageJ 1.46r (49). The running position of protein oxidation states were determined by the band patterns for fully oxidized and fully reduced proteins. The rectangle tool was used to fully enclose the protein bands. For each sample, bands for oxidized and reduced protein were selected and optical parameters were measured automatically. The integrated density was used as readout for the protein amount. The differences between reduced and oxidized protein proportions were compared to values for fully oxidized or reduced samples. These samples were set to 100 % oxidized or reduced, respectively. For redox equilibrium determination, values of reduced protein proportion (in percent) were logarithmically plotted against the concentration ratio of reduced and oxidized glutathione $[GSH]^2/[GSSG]$. The average of the initial and final values were set to 0 % and 100 % reduced, respectively. These scaled curves were fitted using Igor Pro 6.32A (Wavemetrics, Lake Oswego, OR) and the $[GSH]^2/[GSSG]$ ratio at the

point of inflection of the curve was used for the standard redox potential determination. The Nernst equation was applied assuming a standard redox potential of the GSH/GSSG couple of -240 mV (50).

Quikchange mutagenesis of E5

To exchange cysteines within the CXXC motif of E5 to serine, Quikchange mutagenesis was performed as described above. Transformation and sequence verification were performed as described above.

Size exclusion chromatography

Analytical gel filtration was performed as previously described (51). Briefly E5 and E5 C77S was separated on an ÄKTA FPLC system running a Superdex 75 10/300 GL column (GE Healthcare) at $0.5 \text{ ml} \cdot \text{min}^{-1}$ in 50 mM Phosphate buffer containing 150 mM NaCl.

Data Availability: All data, such as sequence data and accession numbers are contained within the article and the supplementary material.

Acknowledgments

We are grateful to Drs. Julia E. Bandow, Ursula Jakob and James C. A. Bardwell for the helpful suggestions regarding all aspects of the manuscript.

Funding and additional information: Principal funding for this work was provided by the European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013) / ERC Grant agreement n° 281384–FuMe and the German Research Foundation (DFG) grant SPP 1710 LE2905/1-2 to L.I.L and LI984/3-1 to C.H.L. Computational work was supported by de.NBI, a project of the German Federal Ministry of Education and Research (BMBF), grant number FKZ 031 A 534A. This manuscript has been written in part during a Writing Retreat funded by the Ruhr-Universität Bochum Research School RURS^{plus}.

Conflict of interest: The authors declare no conflicts of interest in regards to this manuscript.

References

1. Höög, J. O., Jörnvall, H., Holmgren, A., Carlquist, M., and Persson, M. (1983) The primary structure of *Escherichia coli* glutaredoxin. Distant homology with thioredoxins in a superfamily of small proteins with a redox-active cystine disulfide/cysteine dithiol. *Eur. J. Biochem.* **136**, 223–32
2. Perez-Jimenez, R., Inglés-Prieto, A., Zhao, Z.-M., Sanchez-Romero, I., Alegre-Cebollada, J., Kosuri, P., Garcia-Manyes, S., Kappock, T. J., Tanokura, M., Holmgren, A., Sanchez-Ruiz, J. M., Gaucher, E. A., and Fernandez, J. M. (2011) Single-molecule paleoenzymology probes the chemistry of resurrected enzymes. *Nat. Struct. Mol. Biol.* **18**, 592–596
3. Collet, J.-F., and Messens, J. (2010) Structure, function, and mechanism of thioredoxin proteins. *Antioxid. Redox Signal.* **13**, 1205–1216
4. Sousa, S. F., Neves, R. P. P., Waheed, S. O., Fernandes, P. A., and Ramos, M. J. (2019) Structural and mechanistic aspects of S-S bonds in the thioredoxin-like family of proteins. *Biol. Chem.* **400**, 575–587
5. Martin, J. L. (1995) Thioredoxin--a fold for all reasons. *Structure.* **3**, 245–50
6. Martin, P., DeMel, S., Shi, J., Gladysheva, T., Gatti, D. L., Rosen, B. P., and Edwards, B. F. (2001) Insights into the structure, solvation, and mechanism of ArsC arsenate reductase, a novel arsenic detoxification enzyme. *Structure.* **9**, 1071–1081
7. Wang, S., Trumble, W. R., Liao, H., Wesson, C. R., Dunker, A. K., and Kang, C. H. (1998) Crystal structure of calsequestrin from rabbit skeletal muscle sarcoplasmic reticulum. *Nat. Struct. Biol.* **5**, 476–483
8. Aslund, F., and Beckwith, J. (1999) The thioredoxin superfamily: redundancy, specificity, and gray-area genomics. *J. Bacteriol.* **181**, 1375–1379
9. Moutevelis, E., and Warwicker, J. (2004) Prediction of pKa and redox properties in the thioredoxin superfamily. *Protein Sci.* **13**, 2744–2752
10. Yooseph, S., Sutton, G., Rusch, D. B., Halpern, A. L., Williamson, S. J., Remington, K., Eisen, J. A., Heidelberg, K. B., Manning, G., Li, W., Jaroszewski, L., Cieplak, P., Miller, C. S., Li, H., Mashiyama, S. T., Joachimiak, M. P., van Belle, C., Chandonia, J.-M., Soergel, D. A., Zhai, Y., Natarajan, K., Lee, S., Raphael, B. J., Bafna, V., Friedman, R., Brenner, S. E., Godzik, A., Eisenberg, D., Dixon, J. E., Taylor, S. S., Strausberg, R. L., Frazier, M., and Venter, J. C. (2007) The Sorcerer II Global Ocean Sampling expedition: expanding the universe of protein families. *PLoS Biol.* **5**, e16

11. Finn, R. D., Bateman, A., Clements, J., Coghill, P., Eberhardt, R. Y., Eddy, S. R., Heger, A., Hetherington, K., Holm, L., Mistry, J., Sonnhammer, E. L. L., Tate, J., and Punta, M. (2014) Pfam: the protein families database. *Nucleic Acids Res.* **42**, D222-30
12. Enright, A. J., Van Dongen, S., and Ouzounis, C. A. (2002) An efficient algorithm for large-scale detection of protein families. *Nucleic Acids Res.* **30**, 1575–1584
13. Gonzalez Porqué, P., Baldesten, A., and REICHARD, P. (1970) The involvement of the thioredoxin system in the reduction of methionine sulfoxide and sulfate. *J. Biol. Chem.* **245**, 2371–2374
14. Vlamis-Gardikas, A., Potamitou, A., Zarivach, R., Hochman, A., and Holmgren, A. (2002) Characterization of *Escherichia coli* null mutants for glutaredoxin 2. *J. Biol. Chem.* **277**, 10861–10868
15. Bardwell, J. C., Lee, J. O., Jander, G., Martin, N., Belin, D., and Beckwith, J. (1993) A pathway for disulfide bond formation in vivo. *Proc. Natl. Acad. Sci. U. S. A.* **90**, 1038–1042
16. Dailey, F. E., and Berg, H. C. (1993) Mutants in disulfide bond formation that disrupt flagellar assembly in *Escherichia coli*. *Proc. Natl. Acad. Sci. U. S. A.* **90**, 1043–1047
17. Shevchik, V. E., Condemine, G., and Robert-Baudouy, J. (1994) Characterization of DsbC, a periplasmic protein of *Erwinia chrysanthemi* and *Escherichia coli* with disulfide isomerase activity. *EMBO J.* **13**, 2007–2012
18. Hiniker, A., and Bardwell, J. C. A. (2004) In vivo substrate specificity of periplasmic disulfide oxidoreductases. *J. Biol. Chem.* **279**, 12967–12973
19. Majdalani, N., Heck, M., Stout, V., and Gottesman, S. (2005) Role of RcsF in signaling to the Rcs phosphorelay pathway in *Escherichia coli*. *J. Bacteriol.* **187**, 6770–6778
20. Castanié-Cornet, M.-P., Cam, K., and Jacq, A. (2006) RcsF is an outer membrane lipoprotein involved in the RcsCDB phosphorelay signaling pathway in *Escherichia coli*. *J. Bacteriol.* **188**, 4264–4270
21. Fiedler, W., and Rotering, H. (1988) Properties of *Escherichia coli* mutants lacking membrane-derived oligosaccharides. *J. Biol. Chem.* **263**, 14684–14689
22. Leverrier, P., Vertommen, D., and Collet, J.-F. (2010) Contribution of proteomics toward solving the fascinating mysteries of the biogenesis of the envelope of *Escherichia coli*. *Proteomics.* **10**, 771–784
23. Holmgren, A. (1979) Thioredoxin catalyzes the reduction of insulin disulfides by dithiothreitol and dihydrolipoamide. *J. Biol. Chem.* **254**, 9627–9632
24. Krause, G., and Holmgren, A. (1991) Substitution of the conserved tryptophan 31 in *Escherichia coli* thioredoxin by site-directed mutagenesis and structure-function analysis. *J. Biol. Chem.* **266**, 4056–4066
25. Wunderlich, M., and Glockshuber, R. (1993) Redox properties of protein disulfide isomerase (DsbA) from *Escherichia coli*. *Protein Sci.* **2**, 717–726
26. Zapun, A., Missiakas, D., Raina, S., and Creighton, T. E. (1995) Structural and functional characterization of DsbC, a protein involved in disulfide bond formation in *Escherichia coli*. *Biochemistry.* **34**, 5075–5089
27. Holmgren, A., Söderberg, B. O., Eklund, H., and Brändén, C. I. (1975) Three-dimensional structure of *Escherichia coli* thioredoxin-S2 to 2.8 Å resolution. *Proc. Natl. Acad. Sci. U. S. A.* **72**, 2305–2309

28. Kallis, G. B., and Holmgren, A. (1980) Differential reactivity of the functional sulfhydryl groups of cysteine-32 and cysteine-35 present in the reduced form of thioredoxin from *Escherichia coli*. *J. Biol. Chem.* **255**, 10261–10265
29. Motohashi, K., Kondoh, A., Stumpp, M. T., and Hisabori, T. (2001) Comprehensive survey of proteins targeted by chloroplast thioredoxin. *Proc. Natl. Acad. Sci. U. S. A.* **98**, 11224–11229
30. Li, W., and Godzik, A. (2006) Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. *Bioinformatics.* **22**, 1658–1659
31. Eddy, S. R. (2011) Accelerated Profile HMM Searches. *PLoS Comput. Biol.* **7**, e1002195
32. Katoh, K., and Standley, D. M. (2013) MAFFT multiple sequence alignment software version 7: Improvements in performance and usability. *Mol. Biol. Evol.* **30**, 772–780
33. Grote, A., Hiller, K., Scheer, M., Münch, R., Nörtemann, B., Hempel, D. C., and Jahn, D. (2005) JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. *Nucleic Acids Res.* **33**, W526–W531
34. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990) Basic local alignment search tool. *J. Mol. Biol.* **215**, 403–410
35. Kozak, M. (1983) Comparison of initiation of protein synthesis in procaryotes, eucaryotes, and organelles. *Microbiol. Rev.* **47**, 1–45
36. Petersen, T. N., Brunak, S., von Heijne, G., and Nielsen, H. (2011) SignalP 4.0: discriminating signal peptides from transmembrane regions. *Nat. Methods.* **8**, 785–786
37. Gasteiger, E., Hoogland, C., Gattiker, A., Duvaud, S., Wilkins, M. R., Appel, R. D., and Bairoch, A. (2005) Protein Identification and Analysis Tools on the ExPASy Server. *Proteomics Protoc. Handb.* 10.1385/1-59259-890-0:571
38. Sambrook, J., and Russell, D. W. (2001) *Molecular Cloning: A Laboratory Handbook*, 3rd Ed. (Sambrook, J., and Russell, W. eds), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
39. Datsenko, K. A., and Wanner, B. L. (2000) One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc. Natl. Acad. Sci. U. S. A.* **97**, 6640–6645
40. Rentier-Delrue, F., Swennen, D., and Martial, J. (1988) pIN-III-ompA secretion vectors: modification of the ompA signal peptide sequence for easier insert cloning. *Nucleic Acids Res.* **16**, 8726
41. Moore, S. D., and Prevelige, P. E. (2002) A P22 scaffold protein mutation increases the robustness of head assembly in the presence of excess portal protein. *J. Virol.* **76**, 10245–10255
42. Neidhardt, F. C., Bloch, P. L., and Smith, D. F. (1974) Culture medium for enterobacteria. *J. Bacteriol.* **119**, 736–747
43. Arnold, K., Bordoli, L., Kopp, J., and Schwede, T. (2006) The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. *Bioinformatics.* **22**, 195–201
44. Dolinsky, T. J., Czodrowski, P., Li, H., Nielsen, J. E., Jensen, J. H., Klebe, G., and Baker, N. A. (2007) PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. *Nucleic Acids Res.* **35**, W522–5
45. Humphrey, W., Dalke, A., and Schulten, K. (1996) VMD: visual molecular dynamics. *J. Mol. Graph.* **14**, 33–8, 27–8
46. Baker, N. A., Sept, D., Joseph, S., Holst, M. J., and McCammon, J. A. (2001) Electrostatics of

- nanosystems: application to microtubules and the ribosome. *Proc. Natl. Acad. Sci. U. S. A.* **98**, 10037–41
47. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E. (2004) UCSF Chimera--a visualization system for exploratory research and analysis. *J. Comput. Chem.* **25**, 1605–12
 48. Lindemann, C., Lupilova, N., Müller, A., Warscheid, B., Meyer, H. E., Kuhlmann, K., Eisenacher, M., and Leichert, L. I. (2013) Redox proteomics uncovers peroxynitrite-sensitive proteins that help *Escherichia coli* to overcome nitrosative stress. *J. Biol. Chem.* **288**, 19698–19714
 49. Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012) NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods.* **9**, 671–675
 50. Schafer, F. Q., and Buettner, G. R. (2001) Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. *Free Radic. Biol. Med.* **30**, 1191–1212
 51. Müller, A., Langklotz, S., Lupilova, N., Kuhlmann, K., Bandow, J. E., and Leichert, L. I. O. (2014) Activation of RidA chaperone function by N-chlorination. *Nat. Commun.* **5**, 5804



17




Figure 2: Plasmids used in this study. pCC (plasmid for Cytoplasmic Complementation) and pPC (plasmid for Periplasmic Complementation) are derivatives of pTAC-MAT-Tag-2 (Sigma-Aldrich, St. Louis, MO). pOE (plasmid for OverExpression) is a derivative of pET-11a (Agilent, Santa Clara, CA). Thioredoxin superfamily members were inserted between *NdeI* (containing the original gene's start codon ATG) and *EcoRI*. Inserted genes contained a stop codon before *EcoRI*. For vector sequences see also supplementary material S2.




Figure 3: Rescue of phenotypes of thioredoxin superfamily member knockouts in *E. coli*. (A) Schematic of the *trxA* complementation assay. *E. coli* wildtype is able to grow on sulfate as the only sulfur source using 3'-Phosphoadenosine-5'-phosphosulfate-reductase (PAPS red)-dependent sulfate assimilation. PAPS red itself is reduced by thioredoxin (TrxA) or one of the several glutaredoxins (GrxA, GrxB, GrxC). The knockout mutant of glutathione oxidoreductase (*E. coli* Δ *gor*) effectively inactivates the glutaredoxins, but the strain is still able to grow on sulfate as the sole sulfur source, because TrxA is sufficient to reduce PAPS red. A Δ *gor* Δ *trxA* double mutant (*E. coli* Δ *gor/trxA*) is no longer able to reduce PAPS red. The introduction of *trxA* from a plasmid (pCC_*trxA*) restores PAPS red reduction. (B) A Δ *gor/trxA* double mutant is not viable in minimal medium containing sulfate as the sole sulfur source. Expression of *E. coli* TrxA from plasmid pCC rescues the phenotype. (C) *E. coli* wildtype expresses functional flagella containing an essential disulfide bond in the FlgI subunit of the flagellar motor. This disulfide bond is introduced by the thiol-disulfide oxidoreductase DsbA. A knockout mutant lacking DsbA (*E. coli* Δ *dsbA*) is lacking functional flagella. Reintroduction of DsbA from a plasmid (pPC_*dsbA*) restores structural disulfide bonds in FlgI. (D) A Δ *dsbA* mutant is non-motile. Expression of *E. coli* DsbA from plasmid pPC rescues the phenotype. (E) *E. coli* wildtype is non-mucoid. A knockout in MdoG (*E. coli* Δ *mdoG*) leads to a mucoid phenotype, as RcsF senses envelope stress and initiates a signaling cascade resulting in the production of colanic acid. The correct disulfide connectivity in RcsF is dependent on the isomerase DsbC, thus a mutant lacking both MdoG and DsbC (*E. coli* Δ *mdoG/dsbC*) is non-mucoid. Expression of DsbC from a plasmid (pPC_*dsbC*) restores mucoidity in this double mutant. (F) A Δ *mdoG/dsbC* double knock forms non-mucoid colonies. Expression of *E. coli* DsbC without export signal sequence (-SS) from plasmid pPC restores mucoidity.






Figure 4: Complementation assays for the assignment of functions to metagenomic thioredoxin superfamily members. (A) Growth phenotypes of $\Delta gor \Delta trxA$ strains expressing 100 metagenomic thioredoxin superfamily members. A $\Delta gor \Delta trxA$ strain of *E. coli* is unable to grow in a minimal medium containing sulfate as the sole sulfur source (see figure 3 A for a schematic). Only if a metagenomic reductase expressed from a plasmid acts on PAPS reductase, the phenotype will be rescued. Metagenomic thioredoxin superfamily members rescuing the phenotype are highlighted in blue. (C) Motility phenotypes of $\Delta dsbA$ strains expressing 100 metagenomic thioredoxin superfamily members. A $\Delta dsbA$ strain is non-motile (see figure 3 C for a schematic). A metagenomic oxidase expressed from a plasmid could rescue the associated phenotype if it is able to introduce a structural disulfide in the bacterias flagella. Thioredoxin superfamily members restoring motility are highlighted in green. (D) Mucoidity of $\Delta mdoG \Delta dsbC$ strains expressing 100 metagenomic thioredoxin superfamily members. A $\Delta mdoG \Delta dsbC$ strain has a non-mucoid phenotype (see figure 3 E for a schematic). Mucoidity could be restored by a metagenomic isomerase that can isomerize the correct disulfides in RcsF. Thioredoxin superfamily members rescuing RcsF function are highlighted in red. Representative results, all experiments were repeated at least three times.




Figure 5: Relation of assigned function with phylogeny of thioredoxin superfamily members and the isosurfaces of the electrostatic potential of reductases. (A) 27 (out of 100) thioredoxin superfamily members were assigned a function based on our complementation assays. 12 superfamily members rescued more than one phenotype. (B-D) Phylogenetic trees and evolutionary distance of *E. coli* thioredoxins and their metagenomic counterparts. (B) Metagenomic reductases, (C) metagenomic isomerases, (D) metagenomic oxidases. See also figure 1 for how these proteins relate to each other and to the other thioredoxins identified in the GOS dataset. The presumed root of the tree is marked by a bar. Alignments of the metagenomic reductases, oxidases, and isomerases can be found in supplementary material S3. (E) Isoelectric surface charge of *E. coli* TrxA. (F) Isosurfaces of the electrostatic potential

based on predicted structures of metagenomic reductases. Orientation of the proteins is identical based on the structural alignment with *E. coli* TrxA's structure. (G) Consensus isosurfaces of all metagenomic reductases. For predicted isoelectric surfaces of all metagenomic thioredoxins see figure S1. For predicted isoelectric surfaces of metagenomic oxidases and isomerases see figure S2.




Figure 6: *E. coli* TrxA, DsbC, and DsbA only rescue their respective phenotype. No overlapping function was detected in the selected assays. The native signal sequence for periplasmic export was removed from DsbC and DsbA (-SS).




Figure 7: Insulin reduction activity and mid-point redox potential of thioredoxin superfamily members. (A) Representative insulin reduction activity measurement of *E. coli* TrxA and the metagenomic reductases G5 and C12, TrxA's phylogenetically most closely and distantly related thioredoxin superfamily members. (B) Relative insulin reduction activity of metagenomic thioredoxin superfamily members. Activity of *E. coli* TrxA was set to 1. Color coding according to function (cf. figure 5 A). (C) Representative redox potential determination of metagenomic thioredoxin G5. Arrows labelled "red" and "ox" indicate the migration of the AMS-treated reduced and oxidized G5, respectively. M: Marker. Due to the limited number of available pockets on an SDS-gel, samples were run on two separate gels, the dashed lane marks the splice border (D) Standard redox potential E_0 of metagenomic thioredoxin superfamily members. Color coding according to function (cf. figure 5 A).




Figure 8: Metagenomic thioredoxin E5 is a new i thioredoxin superfamily member with an unusual reaction mechanism. (A) E5 is an effective disulfide isomerase in the commercial *E. coli* SHUFFLE™ strain and can support oxidative folding of several proteins, including vtPA, which contains 9 disulfide bonds when folded correctly. (B) It shows higher initial velocity than *E. coli* TrxA in an insulin reduction assay. (C) Redox potential determination of E5 using AMS, as described in figure 7 C. When oxidized in a glutathione redox buffer, E5 forms disulfide-linked dimers, which can be observed in non-reducing SDS PAGE. M: Marker, MW in kDa indicated on the right, ox. and red.: fully oxidized and reduced E5 respectively. (D) The redox potential can be calculated from the ratio of reduced and oxidized protein in a given glutathione redox buffer based on the Nernst equation. Based on these calculations, E5 has a standard redox potential of -246 mV, close to the redox potential of thioredoxin. (E) Reduced E5 and *E. coli* TrxA reduce insulin when no DTT for enzyme recycling is added. (F) E5 protein oxidized in this reaction forms disulfide-linked dimers, which can be observed in a Coomassie-stained SDS PAGE. Higher molecular weight species indicated by arrows are presumably insulin adducts to the E5 dimer and E5 multimers cross-linked by insulin. (G) An E5 C77S mutant, which contains only 1 cysteine, still forms a disulfide-linked dimer when oxidized with diamide and (H) is still active in an insulin reduction assay, while an E5 C74S mutant is inactive. (I) Size exclusion chromatography of E5 and its C77S mutant suggests a molecular weight consistent approximately with a homo-hexamer (the calculated mass of E5 is 23580 Da), when compared to a protein mixture used as standard (THY: Thyroglobulin, FER: Ferritin, ALD: Aldolase, CON: Conalbumin, OVA: Ovalbumin, CAR: Carbonic anhydrase, RIB: Ribonuclease). To calculate the molecular weight of E5, high and low molecular weight standard proteins were run in separate runs and their molecular mass plotted against the elution volume. The plot was fitted using an exponential function in Excel.




Figure 9: Ellman's assay to determine free thiols in reduced and oxidized metagenomic thioredoxin representative E5. DTNB and diamide-oxidized or DTT-reduced E5 protein (50 μ M) was added to Potassium phosphate buffer. As a control, no protein was added (DTNB only) and release of TNB was monitored at 412 nm over time.




Figure 10: An E5 C77S mutant lacking the resolving cysteine does not complement the DsbA phenotype.

Functional metagenomics of the Thioredoxin superfamily

Sebastian Nilewski, Marharyta Varatnitskaya, Thorsten Masuch, Anna Kusnezowa, Manuela Gellert, Anne F. Baumann, Natalie Lupilov, Witali Kusnezow, Markus-Hermann Koch, Martin Eisenacher, Mehmet Berkmen, Christopher Horst Lillig and Lars I. Leichert

J. Biol. Chem. published online December 24, 2020

Access the most updated version of this article at doi: [10.1074/jbc.RA120.016350](https://doi.org/10.1074/jbc.RA120.016350)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts